Kaneka Corp. is increasing its GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A., a wholly owned group company in Europe. The company plans to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is approximately 5 times higher than the current capacity. 
 
mRNA, which has been used in COVID-19 vaccines, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases and cancer. The demand for GMP manufacturing of mRNA will increase with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
 
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals and is inspected by the U.S. FDA with world-class technology for producing plasmid DNA and GMP manufacturing. The company provides plasmid DNA, recombinant proteins, oligonucleotide as drug substances for pharmaceutical companies worldwide. Kaneka Eurogentec S.A. began GMP manufacturing services for mRNA in 2020, and this capacity expansion will be utilized to expand the CDMO business.